HPV-FASTER is an innovative public health intervention combining HPV vaccination and HPV-based screening in adult women at the same visit. FASTER-Tlalpan adapted the combined HPV-FASTER strategy in Tlalpan, Mexico City for women aged 25-45 years. To understand the barriers and facilitators to participation in a combined strategy, we conducted semi-structured interviews with 14 FASTER-Tlalpan participants. We used the constant comparative method for the analysis, as well as the socioecological model to organize the findings. At the intrapersonal level, barriers included the belief that only younger women are at risk for HPV, embarrassment about the pelvic exam, and lack of time, while facilitators were having information regarding the benefit of the combined strategy, perception of time saved by having both procedures at once, feeling reassured about their health, self-esteem regarding their health, and perceived severity of cervical cancer. Interpersonal-level barriers were experiences of stigma and prejudice, and lack of support from partners, while facilitators were family encouragement and peer-to-peer communications. Institutional-level barriers were lack of infrastructure and inconvenient hours at the health center, perceived high time burden, and low quality of care from providers, while facilitators included high-quality care by health center personnel, including partners in the combined strategy, and phone reminders. Community-level facilitators included willingness to participate. Public policy facilitators included mass information campaigns and free procedures. Our findings point to significant barriers which need to be addressed, along with facilitators which can be leveraged to scale up the combined strategy in similar settings.

The lymphocyte-to-C-reactive protein ratio (LCR) is a promising inflammation-based tool for assessing the status of patients with malignant tumours. This study evaluated the ability of LCR to predict the prognosis of patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC) after chemoradiotherapy.

We retrospectively investigated 206 consecutive patients with unresectable LA-NSCLC who underwent chemoradiotherapy between January 2016 and November 2019. The LCR was calculated from the differential count by dividing the absolute lymphocyte count by the C-reactive protein level. The optimal cut-off value of LCR was determined using the receiver operating characteristic (ROC) curve, and the enrolled patients were divided into two groups for further analysis according to LCR. Overall survival (OS) and disease-free survival (DFS) were assessed using univariate and multivariate Cox regression analyses.

In patients with unresectable LA-NSCLC, the level of LCR was significantly associated with pathology (p = 0.042) and TNM stage (p = 0.002). High LCR and low LCR patients had different distinct outcomes (median OS: 36 vs. 34 months, p < 0.0001) and recurrence risk (median DFS: 31 vs. 23 months, p < 0.001). Univariate analysis indicated that Eastern Cooperative Oncology Group (ECOG) performance status, TNM stage, CEA level, response, neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), systemic immune inflammation index (SII), and LCR were predictors of OS and DFS. Multivariate analysis showed that a high LCR was an independent prognostic factor for OS (hazard ratio [HR], 0.526; 95% CI, 0.364-0.762; p = 0.001) and DFS (HR, 0.390; 95% CI, 0.275-0.554; p < 0.001).

LCR is a promising prognostic index in patients with LA-NSCLC undergoing chemoradiotherapy, and an increase in the LCR level contributes to better outcomes.

Chronic liver diseases, including metabolic dysfunction-associated steatosic liver disease (MASLD) and hepatocellular carcinoma (HCC), are on the rise, potentially due to daily exposure to complex mixtures of chemical compounds forming part of the exposome. Understanding the mechanisms involved in hepatotoxicity of these mixtures is essential to identify common molecular targets that may highlight potential interactions at the molecular level. We illustrated this issue with two families of environmental contaminants, per- and polyfluoroalkyl substances (PFAS) and heterocyclic aromatic amines (HAAs), both of which could be involved in the progression of chronic liver diseases, and whose toxicity may be potentiated by interactions at the level of xenobiotic metabolism. In the study of exposome effects on chronic liver disease, New Approach Methodologies (NAMs) including omics analyses and data from various in vitro, in vivo and in silico approaches, are crucial for improving predictivity of toxicological studies in humans while reducing animal experimentation. Additionally, the development of complex in vitro human liver cell models, such as organoids, is essential to avoid interspecies differences that minimize the risk for humans. All together, these approaches will contribute to construct Adverse Outcome Pathways (AOPs) and could be applied not only to PFAS mixtures but also to other chemical families, providing valuable insights into mixture hepatotoxicity prediction in the study of the exposome. A better understanding of toxicological mechanisms will clarify the role of environmental contaminant mixtures in the development of MASLD and HCC, supporting risk assessment for better treatment, monitoring and prevention strategies.

Objective   68 Ga-PSMA-HBED-CC positron emission tomography (PET)/computed tomography (CT) represents a clinically relevant technique for the evaluation of prostate cancer (PCa) patients, whereas 18 F-AIF-PSMA-HBED-CC is a novel tracer produced in our center, with suitable radiochemical purity for clinical purposes. We prospectively compared the diagnostic values of both tracers for the detection of metastatic disease in patients with intermediate-/high-risk PCa at initial staging. Materials and Methods  Sixty-six patients (mean age: 63 years; range: 52-78 years) with PCa at initial staging (Gleason score ≥6; median prostate-specific antigen [PSA]: 10 ng/mL; range:1.7-152 ng/mL) prospectively underwent routine 68 Ga-PSMA-11 and 18 F-AlF-PSMA-11 PET/CT scanning with a 64-slice PET/CT scan with time-of-flight (TOF) correction. We measured the maximum standardized uptake value (SUVmax) and lesion-to-background ratio (LBR) in all coincidentally detected lesions. Open prostatectomy and pelvic lymph node dissection were performed in nonmetastatic patients. Histopathology, correlative imaging, and/or clinical follow-up were considered the gold standard. Follow-up was conducted at least 4 months after PET/CT scanning (median: 6.4 months; range: 4-11 months). Sensitivity, specificity, and predictive values were calculated. Results  The overall detection rate was 85% (56/66) for both tracers. At least one suspicious lesion indicating potential PCa metastasis was detected in 20 (30%) and 21 (32%) of 66 patients for 68 Ga-PSMA-11 and 18 F-AIF-PSMA-11 tracers, respectively. A total of 145 extra-prostatic lesions were detected in the bone ( n  = 56), lymph nodes ( n  = 88), and lung ( n  = 1) by at least one radiopharmaceutical: 131 (90%) for 68 Ga-PSMA-11 and 123 (85%) for 18 F-AlF-PSMA-11. In concordant lesions, a significant correlation was found between the SUVmax of both tracers ( r  = 0.90, p  = 0.001). The SUVmax and LBR for 18 F-AlF-PSMA-11 were higher in bone foci ( n  = 39) compared with 68 Ga-PSMA-11 (7.2 vs. 8.9 and 14 vs. 13, respectively, p  = 0.02). For the detection of systemic metastasis, the sensitivity values were the same for both techniques: 0.90 (95% confidence interval [CI]: 0.68-0.98). We calculated specificities of 0.96 (95% CI: 0.85-0.99) and 0.94 (95% CI: 0.82-0.98) for 68 Ga-PSMA-11 and 18 F-AlF-PSMA-11, respectively. Conclusions   68 Ga-PSMA-11 and 18 F-AlF-PSMA-11 PET/CT seem to be clinically equivalent imaging techniques for the assessment of primary intermediate-/high-risk PCa with promising potential for the detection of metastatic spread that would impact patient management.

Traditional radiotherapy (RT) lacks the precision to distinguish between tumor and normal tissues, leading to inevitable X-ray-induced side effects in patients. Therefore, it is crucial to develop integrated imaging and therapeutic modalities that can reduce side effects on surrounding healthy tissues while enhancing susceptibility to tumor tissues. In this study, we developed a pH-responsive nanodrug (AuNRs-Mn3O4-Ag2S Ve) by self-assembling the second near-infrared (NIR-II, 950-1700 nm) fluorescent probe Ag2S quantum dots (QDs), multifunctional nanozyme Mn3O4 nanoparticles (NPs), and radiosensitizer gold nanorods (AuNRs) into a single nanoplatform via an emulsion process. This nanodrug enables precise tumor localization for accurately guided RT and multi-angle sensitization of RT. Upon intravenous administration, the nanodrug disintegrates in the tumor area due to the pH-sensitive polymer P4VP, releasing Ag2S QDs which are specifically activated by the acidic environment, thereby "turning on" the NIR-II fluorescence signal. The optimal timing of the NIR-II fluorescence signal within the tumor region after intravenous injection was investigated, providing a reference for guided RT. In vitro and in vivo experiments confirmed the efficient enhancement of tumor radiosensitization by AuNRs and Mn3O4 NPs. The specific imaging modality that transitions the fluorescence signal from "off" to "on" has been successfully implemented, addressing the limitations of conventional RT and enhancing radiosensitivity. The integration of imaging and therapeutic approaches in this study presents a promising modality for image-guided tumor RT.

The requirement for relevant and safe drugs for cancer treatment is considered a challenge. Recently, marine isolated compounds with various therapeutic targets have attracted many researchers.

Isolation and identification of potential anticancer peptides from edible Callista chione soft tissues.

C. chione specimens were collected and peptides were extracted, purified with FPLC, and tested on normal (hepatocytes and VERO) and cancer (HepG2, and HT-29) cells. Bioactive fractions were tested by tandem mass spectrometry.

Five different fractions were purified according to ionic charges and two fractions (4 and 5) showed a potent anticancer activity with a total anticancer score threshold of ≥ 0.5, and hydrophilicity mean of 1.75 that related to stability and solubility. The apoptotic and autophagy-related markers were significantly up-regulated in both HepG2 and HT-29 cells treated with IC50 of bioactive peptides' fractions 4 and 5, explaining their underlying mechanism of action.

Natural source peptides derived from the soft tissue of C. chione could be exploited for the treatment of cancers and a deep in silico study will be performed for further investigation and deep function identification.

The purpose of the study is to investigate the gender differences among newly diagnosed cancer patients from the cultural perspective of Pakistan. The data comprised two equal groups: men (50%) and women (50%). Most participants were 31-45 years old, and the duration of the cancer diagnosis was less than 6 months (74.6%). The data was collected on the following scales: the discrimination and stigma scale, the internalized stigma scale, the WHO-quality of life scale, and the fear of death scale. Data was analyzed using SPSS v.25; descriptive statistics, an independent sample t-test, and simple linear regression were applied to the data. The results revealed that men and women are both experiencing cancer-related stigmatization in Pakistan. However, women face a higher level of stigmatization, lower quality of life, and higher fear of death than men. Furthermore, the regression analysis result confirms that the cancer-related stigma faced by the diagnosed patients decreases the patient's quality of life and induces the fear of death.

In this work the relationship between Schistosoma mansoni (Sm) and the induction and progression of colorectal cancer (CRC) is examined. Various clinical studies reviewed here yield inconsistent results, with some reporting no association between Sm infection and CRC and others suggesting a probable to strong association. Here we propose a number of plausible mechanisms whereby Sm infection might contribute to CRC induction and/or progression. These factors are (1) chronic inflammation, (2) exposure to parasite linked antigens and genotoxic products, especially soluble egg antigens (SEAs) and (3) alteration of the intestinal microbiota. These factors probably predispose humans towards CRC and can help in CRC progression however only widespread epidemiological, clinical and pathological studies can firmly establish their role or a complete lack of it.

Artificial Intelligence (AI) is capable of revolutionizing cancer therapy and advancing precision oncology via integrating genomics data and digitized health information. AI applications show promise in cancer prediction, prognosis, and treatment planning, particularly in radiomics, deep learning, and machine learning for early cancer diagnosis. However, widespread adoption requires comprehensive data and clinical validation. While AI has demonstrated advantages in treating common malignancies like lung and breast cancers, challenges remain in managing rare tumors due to limited datasets. AI's role in processing multi-omics data and supporting precision oncology decision-making is critical as genetic and health data become increasingly digitized.

This review article presents current knowledge on AI and associated technologies, which are being utilized in the diagnosis and therapy of cancer. The applications of AI in radiomics, deep learning, and machine learning for cancer screening and treatment planning are examined. The study also explores the capabilities and limitations of predictive AI in diagnosis and prognosis, as well as generative AI, such as advanced chatbots, in patient and provider interactions.

AI can improve the early diagnosis and treatment of high-incidence cancers like breast and lung cancer. However, its application in rare cancers is limited by insufficient data for training and validation. AI can effectively process large-scale multi-omics data from DNA and RNA sequencing, enhancing precision oncology. Predictive AI aids in risk assessment and prognosis, while generative AI tools improve patient-provider communication. Despite these advancements, further research and technological progress are needed to overcome existing challenges.

AI holds transformative potential for cancer therapy, particularly in precision oncology, early detection, and personalized treatment planning. However, challenges such as data limitations in rare cancers, the need for clinical validation, and regulatory considerations must be addressed. Future advancements in AI could significantly improve decision-support systems in oncology, ultimately enhancing patient care and quality of life. The review highlights both the opportunities and obstacles in integrating AI into cancer diagnostics and therapeutics, calling for continued research and regulatory oversight.

Circular RNAs (circRNAs) have been reported to be associated with the progression of various tumors including colorectal cancer (CRC). However, the role and underlying mechanism of hsa_circ_0087862 in CRC remains unclear. Hsa_circ_0087862 expression in CRC tissues was analyzed using two GEO datasets (GSE138589 and GSE126094). Expression of hsa_circ_0087862, miR-149-5p and tumor necrosis factor receptor-associated factor 6 (TRAF6) in CRC cells was detected. The subcellular distribution of hsa_circ_0087862 was analyzed using a Cytoplasmic & Nuclear RNA Purification Kit. The function of hsa_circ_0087862 in CRC cells was detected using CCK-8, Transwell invasion assay, flow cytometry analysis, and Caspase-3 activity assay. The relationships between hsa_circ_0087862, miR-149-5p and TRAF6 were detected using luciferase reporter assay, RIP, or biotinylated RNA pull-down assay. Hsa_circ_0087862 was upregulated in CRC tissues and cells. Hsa_circ_0087862 is resistant to RNase R digestion and predominantly localized in the cytoplasm. Interference with hsa_circ_0087862 inhibited the malignant phenotypes of CRC cells by reducing cell proliferation and invasive abilities and triggering apoptosis. Hsa_circ_0087862 silencing inhibited TRAF6 expression by sponging miR-149-5p in CRC cells. Inhibition of miR-149-5p attenuated the effects of hsa_circ_0087862 on the malignant phenotypes of CRC cells. TRAF6 overexpression abolished the effects of miR-149-5p on cell growth, invasion and apoptosis in CRC cells. In conclusion, hsa_circ_0087862 silencing inhibited the malignant behaviors of CRC cells through inhibiting TRAF6 expression by sponging miR-149-5p.

The effect of statin use on hepatocellular carcinoma (HCC) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) or type two diabetes mellitus (T2DM) is still unclear. In this umbrella review, we aimed to assess the available evidence for the association of statin use and HCC risk in the target population.

We carried out an umbrella review of previous systematic reviews/meta-analyses indexed in Cochrane, Embase, Scopus, and PubMed databases and published between Jan 1st, 2013, and Oct 22, 2024. We used random effects models to recalculate summary risk estimates for HCC incidence. Using A Measurement Tool to Assess methodological quality of systematic Review (AMSTAR2) tool, two independent reviewers evaluated each article for eligibility and methodologic quality and gathered data from the included studies.

Of the initially identified 1,038 systematic reviews/meta-analyses, three non-overlapping studies with medium/high quality were included for qualitative synthesis. Statin use in people with T2DM was reported in six studies belonging to two meta-analyses. The results showed that statins were associated with a decreased risk of HCC (RR: 0.16, 95% CI: [0.03, 0.98]). However, the association was nonsignificant in patients with MASLD comprising five studies from one meta-analysis (RR: 0.89, 95% CI: [0.56, 1.40]).

Statin use is associated with a decreased incidence of HCC in people with T2DM. In patients with MASLD, the association is not significant. However, the effects of other variables including the stage of inflammation and/or liver fibrosis on the outcome need to be explored in future studies.

HPV self-sampling has the potential to improve early detection of cervical cancer among women living with HIV (WLHIV), but its acceptability varies, creating implementation challenges, especially in sub-Saharan Africa. This study aims to assess the acceptability of HPV self-sampling among WLHIV. We searched PubMed, Web of Science, CINAHL, Academic Medical Ultimate, Cochrane databases, and Google Scholar. The review protocol was registered with PROSPERO (CRD42022299781). Inclusion criteria were based on population, intervention, comparison, and outcome. Statistical analysis was done with R Studio version 4.3.2, and data abstraction was performed in Microsoft Excel. The analysis included 14 studies on the acceptability of HPV self-sampling among WLHIV. The overall acceptability rate was 73%. The pooled data showed that 94% felt comfortable with self-sampling, 72% found it easy to use, 10% reported pain, 14% felt embarrassed, and 41% felt confident about the process. The study found that a majority of WLHIV accepted HPV self-sampling, a higher rate than in the general female population. Many participants had concerns about the method's efficacy. This indicates that while WLHIV generally views self-sampling positively, additional education and support are needed to improve their confidence in its accuracy and reliability.

We present an epidemiological description of cancer of the lip, oral cavity, and oropharynx focused on South and South-East Asia by cancer site, sex, and population.

The number of new cases and deaths from lip, oral cavity, and oropharynx cancers was extracted from GLOBOCAN 2022 and Cancer Incidence in Five Continents. We present age-standardized incidence and mortality rates (ASR) per 100,000 and temporal trends between 1992 and 2017 for four populations in the Region.

In 2022, there were 177,258 incident cases and 98,735 deaths from oral cancer in this region. ASR for lip and oral cancer in South and South-East Asia was highest in India (14.67), Sri Lanka (14.04), Bangladesh (13.61) and Pakistan (12.07) in males. The highest age-standardized mortality rates for lip and oral cancer were observed in India (8.17), Bangladesh (8.07) and Pakistan (7.74) for males.

Incidence and mortality rates of oral cancer in South and South-East Asia are among the highest globally. 52% of total global deaths from oral cancer are reported from this region. Data suggest a persisting trend and an increase in the incidence of oral cavity cancer among Indian and Bangladeshi males.

Lymphedema secondary to multimodal breast cancer treatment is a relatively common complication that significantly impacts patients' quality of life. Despite identifying several associated risk factors, accurately assessing individual risk remains challenging. This study aims to develop predictive tools integrating patient characteristics, tumor attributes, and treatment modalities to optimize clinical surveillance, enhance prevention, and enable earlier diagnosis.

Data were analyzed from 309 patients referred to the Lymphedema Unit of Rehabilitation Service who underwent lymphadenectomy for breast cancer between January 2016 and December 2021. Collected variables included patient demographics, tumor clinicopathological features, and treatment details. A lymphedema incidence study was conducted, complemented by univariate and multivariate regression analyses to identify risk factors. A nomogram was developed to predict high-risk patients, facilitating personalized prevention and management strategies.

The cumulative incidence of lymphedema was 18.4%. Independent risk factors included high body mass index, sedentary lifestyle, number of positive nodes (N stage), and radiotherapy, particularly targeting the breast, axilla, and supra-infraclavicular regions. The logistic regression model demonstrated an area under the ROC curve (AUC) of 0.75, with acceptable calibration, validating the predictive model.

The predictive tools developed provide healthcare professionals with a means to identify patients at elevated risk of lymphedema, supporting individualized prevention and management.

Endometrial cancer (ECa) is a prevalent gynecological malignancy, with treatment often hindered by metastasis and recurrence driven by cancer stem-like cells. While circular RNAs (circRNAs) are well known for their cytoplasmic roles as microRNA sponges, their nuclear functions remain largely unexplored. This study investigates nuclear circRNAs and their roles in regulating cancer stem-like properties in ECa.

Nuclear RNA sequencing data were analyzed to identify nuclear-enriched circRNAs. The subcellular localization of circGUSBP1 and circZNF680 was assessed via nuclear-cytoplasmic fractionation and RT-qPCR. The functional impact of circGUSBP1 was evaluated using tumorsphere formation, migration, and cisplatin sensitivity assays. Transcriptomic profiling and survival analysis were conducted using circGUSBP1-knockdown ECa cells and The Cancer Genome Atlas (TCGA) dataset.

CircGUSBP1 exhibited a high circular-to-linear transcript ratio and was preferentially nuclear, independent of intron retention. Its expression correlated with NANOG and OCT4 upregulation. Overexpression of circGUSBP1 enhanced tumorsphere formation, whereas circGUSBP1-knockdown (KD) reduced tumorsphere formation, impaired migration, and increased cisplatin sensitivity. Transcriptomic analysis revealed downregulation of stemness-related genes, supporting its role as a transcriptional co-activator. Notably, 230 circGUSBP1-regulated genes were co-targeted by OCT4, including SUPT16H and SUV39H2, chromatin remodelers linked to poor prognosis in ECa patients. Higher GUSBP1 expression, but not GUSB, correlated with worse survival outcomes in TCGA data.

These findings identify circGUSBP1 as a nuclear regulator of cancer stemness. Through circGUSBP1/OCT4 co-regulation of chromatin modulators, circGUSBP1 promotes aggressive tumor behavior, highlighting its potential as a therapeutic target.

The diagnosis and prognosis of hepatocellular carcinoma (HCC) present significant challenges in clinical practice. This study aimed to evaluate the clinical utility of tumor abnormal protein (TAP), Prothrombin induced by vitamin K absence-II (PIVKA-II), and alpha-fetoprotein (AFP) in diagnosing HCC as well as to investigate their prognostic significance in patients with HCC undergoing transarterial chemoembolization.

A total of 93 HCC patients were enrolled and 101 healthy individuals served as controls. Fresh venous blood samples were collected, and TAP, PIVKA-II, and AFP levels were measured by chemiluminescence immunoassay.

Significant differences in TAP, PIVKA-II, and AFP levels were found between HCC patients and healthy individuals. The combined assay of TAP, AFP, and PIVKA-II showed better diagnostic performance for HCC. Patients who underwent transarterial chemoembolization and achieved complete response (CR) had lower levels of prechemotherapy serum TAP, AFP, and PIVKA-II. There are significant differences in levels of TAP, AFP, and PIVKA-II between CR and partial response (PR), CR and stable disease (SD), and CR and progressive disease (PD).

Combined detection of TAP, PIVKA-II, and AFP has better diagnostic performance for HCC. Higher levels of prechemotherapy serum TAP, AFP, and PIVKA-II are significantly associated with poor clinical chemoresponse.

The goal of this work is to compare the Varian TrueBeam plan quality and delivery verification with two Halcyon plans in order to give a Varian Halcyon planning solution for left-sided breast postmastectomy radiotherapy (PMRT). Twenty-five patients who previously received left-sided breast postmastectomy intensity-modulated radiotherapy (IMRT) on TrueBeam were retrospectively selected and replanned using Halcyon. The planning target volume (PTV) included the chest wall, the supra/infra-clavicular region, and the internal mammary region, with a prescribed dose of 50 Gy in 25 fractions (2 Gy/F). For each patient, a Halcyon IMRT (HA-IMRT) plan and a Halcyon volumetric-modulated arc treatment (HA-VMAT) plan were created in addition to the initial TrueBeam fixed-jaws IMRT (TB-IMRT) plan. The conformity index (CI) and homogeneity index (HI) of the PTVs, the dose of organs at risk (OARs), the delivery MUs and time, and the verification passing rate were calculated and compared. Statistical significance was determined with a significance level of 0.05 using the Wilcoxon signed-rank test. HA-IMRT and TB-IMRT made generally clinical equivalence and have tiny differences for target coverage and OAR sparing. HA-IMRT lowered the V10, V20, V30, and Dmean of the ipsilateral lung, the V5, V10, V20, V30, and Dmean of the heart compared to TB-IMRT (p < 0.05). On the other hand, it increased V5 of the ipsilateral lung, Dmean of the contralateral lung, V10 of the contralateral breast, left humeral head, and thyroid, and HI of the target (p < 0.05). No significant differences were found in CI, V5 and V10 of the contralateral lung, V5 and Dmean of the contralateral breast, V30 and Dmax of thyroid, Dmean and Dmax of esophagus, or Dmax of spinal cord (p > 0.05). HA-VMAT showed a better CI but increased most OAR metrics mentioned above than TB-IMRT and/or HA-IMRT (p < 0.05). Both HA-IMRT and HA-VMAT decreased delivery time compared to TB-IMRT (2.96 ± 0.61 min, 0.77 ± 0.11 min, and 3.52 ± 0.92 min, respectively, p < 0.05). The mean gamma passing rates of HA-IMRT and HA-VMAT were also significantly raised compared to TB-IMRT.

To explore whether there is a relationship between perirenal fat area (PFA) and the pathological types of renal cell carcinoma (RCC).

Two hundred ninety-seven cases of RCC patients were included in our study, which is a retrospective analysis. Based on pathological type, we divided the 297 RCC patients into two groups: the clear cell renal cell carcinoma (ccRCC) group (236 cases) and the non-clear cell renal cell carcinoma (non-ccRCC) group (61 cases). Computed tomography (CT) images at the renal vein level were used to measure PFA. A multivariate logistic regression model was employed to examine the connection between various pathological types of RCC and PFA.

Significant differences were observed between ccRCC and non-ccRCC patients in PFA (P = 0.007), contralateral PFA (P = 0.011), weight (P = 0.002), BMI (P < 0.001), pathological stage 1 (P = 0.010), and pathological stage 2 (P = 0.002). To study the link between pathological subtypes and PFA, a multivariate logistic regression model was employed. Stratifying patients by tumor location in the kidney, the multivariate logistic regression analysis showed that when the tumor is located outside the polar lines of the kidney (OPLK), for every 1 cm2 increase in PFA, the probability of developing ccRCC increases by 5% [1.05 (1.01, 1.10) P = 0.0153]. Furthermore, after stratifying patients by tumor location and pathological stage, it was found that in T1 stage patients with tumors located OPLK, for every 1 cm2 increase in PFA, the probability of developing ccRCC increases by 6% [1.06 (1.01, 1.11) P = 0.0300].

When the tumor is located OPLK in T1 stage patients, PFA is positively correlated with ccRCC. Perirenal adipose tissue may be a risk factor for ccRCC.

The utility of the immune prognostic index (IPI) for esophageal squamous cell carcinoma (ESCC) has yet to be established after minimally invasive esophagectomy (MIE). The purpose of this study was to investigate the value of IPI in predicting the prognosis and postoperative adjuvant chemotherapy (AC) benefits of ESCC patients.

Between January 2011 and December 2018, 613 ESCC patients underwent MIE at our center and were divided into two groups: low IPI and high IPI.Log-rank tests were used to compare the overall survival (OS) and disease-free survival (DFS) of patients in different groups based on Kaplan-Meier survival analysis. Differences in clinical characteristics between groups were eliminated by propensity score matching (PSM) analysis. To identify independent risk factors influencing OS and DFS, the Cox proportional risk model was used.

In comparison to the high IPI group, the low IPI group had a better 5-year OS and DFS in both the entire and matched cohorts (P < 0.05). IPI was found to be an independent prognostic factor for OS and DFS in a multivariate analysis of the entire cohort and the matched cohort (P < 0.05). In subgroup analyses of most clinicopathological factors, high IPI was associated with a higher risk of death or recurrence in the matched cohorts. When combined with 8th TNM staging, the 5-year OS and DFS of stage II or III patients with low IPI in the AC group were not different from those in the non-AC group (P > 0.05), and AC of stage III patients with high IPI significantly prolonged 5-year OS and DFS (OS: 37.4% vs 26.2%, P = 0.018; DFS: 33.6% vs 19.8%, P = 0.042).

Preoperative IPI is a promising predictor of ESCC after MIE. For stage III ESCC patients with high IPI, AC can significantly reduce the risk of death or recurrence.

The applicability of venous thromboembolism (VTE) risk assessment models (RAMs), to breast cancer (BC) populations remains unclear. We aimed to compare the efficacy of current RAMs and examine the potential of additional hematologic parameters and thromboelastography (TEG); a point of care test, in improving VTE prediction in breast cancer (BC) patients.

In this pilot study, female BC patients were recruited before chemotherapy and followed for 6-12 months for VTE. VTE risk was assessed using Khorana score, Vienna CATS, PROTECHT, COMPASS-CAT, New Vienna CATSCORE, MDACC CAT, and hypercoagulability status. TEG and hematologic parameters were analyzed, and a modified RAM was developed.

Among 47 patients, 5 (10.6%) developed VTE. PROTECHT was the strongest predictor [area under the curve (AUC) = 0.844], followed by Vienna CATS (AUC = 0.781). Adding immature granulocytes and red blood cell count to PROTECHT optimized prediction (AUC = 0.856).

Incorporating hematologic parameters into PROTECHT may improve VTE risk prediction in BC patients, warranting further evaluation in larger studies.

To address the limitations and complexities associated with tissue biopsy, emerging nanotechnology methods show promise in enhancing the detection and management of oral squamous cell carcinoma and oral potential malignant disorders. Among them, the characterization of the protein corona, the biomolecular layer that envelops materials when exposed to biological fluids, has recently emerged as a powerful tool for distinguishing oncological patients from healthy people.

Building upon recent insights, here we formulated a new diagnostic method for oral squamous cell carcinoma and oral potentially malignant disorders based on the characterization of the personalized protein corona formed on graphene oxide nanosheets when exposed to the plasma of the patients.

The findings highlighted a discernible distinction between oncological subjects and healthy ones, resulting in an overall accuracy of 87%. Subsequently, we applied this method to monitor the progression of the diseases of the patients undergoing treatment, and we observed a trend indicating a convergence of protein profiles between oncological patients and healthy subjects throughout the treatment course.

If further confirmed in larger prospective studies, this new approach could discriminate oral squamous cell carcinoma and oral potentially malignant disorders and can be considered in the management of these oral diseases.

Prostate cancer (CaP) is the leading non-cutaneous cancer in men of African descent, with the higher mortality rates found in sub-Saharan Africa. Early diagnosis, staging, and management of prostate cancer could help curb its mortality rate in SSA. However, access to precise radiological imaging for staging purposes is limited in our setting. We sought to evaluate the correlation between total prostate specific antigen (tPSA) and histological grading of CaP in our resource-limited setting.

We conducted a retrospective review of records of patients treated for biopsy-proven CaP at the AICKH diagnosed between January 2018 and December 2022. We excluded patients who were already on any sort of treatment of bladder outlet obstruction and incomplete charts. We used Spearman correlation coefficients, and ANOVA to evaluate the relationship between tPSA and various grading parameters. A P-value less than 0.05 was considered significant.

We included 327 medical records. The mean tPSA was 112 ± 4.5ng/ml. The most common Gleason score and grade group were 8 (33.8%) and 4 (33.8%) respectively. Perineural involvement was present in 33% of our population. The tPSA had a positive correlation with Gleason score (rho = 0.253, p < 0.001), grade group (rho = 0.296, p < 0.001), perineural involvement (rho = 0.241, p = 0.001) and proportion of sample invasion (rho = 0.171, p = 0.005). A linear and homogenous variance existed in mean tPSA across increasing Gleason score (p < 0.001).

tPSA is a good predictor of the severity of CaP in resource-limited settings and can be used to inform management decisions.

In observational studies, it has been known that garlic or onions have a negative causal relationship with gastric cancer (GC). In this study, we aim to explore the negative causal relationship between garlic or onion and GC through Mendelian randomization (MR) analysis. The instrumental variable selection for MR analysis is single nucleotide polymorphisms associated with garlic or onion, mainly using the inverse variance weighted method, combined with MR Egger, weighted media, simple mode, and weighted modes to evaluate their causal impact on GC. In addition, sensitivity analysis such as Cochran Q test, pleiotropy test, and leave-one-out method were used to evaluate the robustness of the impact of these single nucleotide polymorphisms on GC. The inverse variance weighted method showed a negative correlation between garlic and GC risk (odds ratio = 0.70; 95% confidence interval 0.49-0.99; P = .046), while there was no relationship between onion and GC, and the sensitivity analysis results showed robustness. The current study has revealed that garlic may be a factor in reducing the risk of GC, providing a strategy for preventing and treating GC.

In the CheckMate 214 trial, approximately 40% of patients with advanced renal cell carcinoma (aRCC) treated with nivolumab plus ipilimumab (NIVO + IPI) achieved long-term survival and a durable response to treatment. However, about 20% of patients experienced early disease progression (EDP). This retrospective study aimed to identify predictive factors for EDP among patients with aRCC treated with NIVO + IPI.

We retrospectively analyzed clinical information from patients with aRCC, 19 patients in the EDP group and 40 patients in the control disease group, all of whom were treated with NIVO + IPI at Kurume University Hospital between September 2018 and February 2024.

The EDP group exhibited significantly worse progression-free survival and overall survival compared to the control disease group. Multivariate analyses revealed that a performance states (PS) ≥2 (p=0.0312) and the presence of bone metastases (p=0.0374) were independent predictors of EDP.

Treatment with NIVO + IPI in patients with aRCC who have a poor PS or bone metastases may be linked to a high risk of EDP.

Global comparisons of the burden and impact of cancers of the brain and central nervous system (CNS) are critical for developing effective control strategies and generating etiological hypotheses to drive future research.

National incidence estimates were obtained from GLOBOCAN 2022, and recorded incidence data from the Cancer in Five Continents series, both developed and compiled by the International Agency for Research on Cancer. We examined the estimated age-standardized incidence rates in 185 countries, as well as time trends in recorded incidence in 35 countries, quantifying the direction and change in the magnitude of the rates using the estimated average percentage change (EAPC).

In 2022, 322,000 new cases of brain and CNS tumors were estimated globally. By world region, the highest incidence rate was seen in Northern America (5.46 per 100,000), Eastern Asia (3.95), and Western Europe (5.56). Africa had relatively lower incidence rates. By country and age group, Austria and the U.S. exhibited the highest rates in boys (3.5 in both), while in adolescents and young adults (AYA), Norway had the highest incidence rates in both males (4.7) and females (3.8). Among adults (+ 40yo), the highest rates in males were observed in the Northern European countries of Norway (18.6), Lithuania (18.4), and Latvia (16.7). In terms of time trends, incidence rates tended to be rather stable in most world regions over the last decade, though increases were observed in selected countries. Trends-based predictions indicate that if incidence rates remain stable, population ageing and growth would mean there would be 474,000 new cases by the year 2045, a 47% increase from 2022.

While the increased incidence rates in certain populations require further study, the future predictions based on stable rates to 2045 are of particular concern, with a close to 50% increase in the number of brain and CNS cancer patients expected over the coming decades. A global 2% decline in rates would be needed to ensure the future brain and CNS cancer burden does not exceed present levels.

Hepatocellular carcinoma (HCC) and cholangiocarcinoma are the primary hepatic malignancies with established pathways to transplantation and model for end-stage liver disease (MELD) exception points. Other tumors managed with liver transplantation (LT) include hepatic epithelioid hemangioendothelioma and fibrolamellar HCC. LT for metastatic neuroendocrine tumor has been established with patient selection criteria and a path to MELD exception points. Additionally, recent data on LT for patients with unresectable hepatic colorectal metastases demonstrate increasingly encouraging initial results.

Returning to work (RTW) is a crucial aspect of recovery for patients with breast cancer (BC), which indicates restored normalcy, financial stability, functional abilities, and an improved quality of life. However, associated factors related to not RTW among patients with BC remain unclear. In this study, we examined associated factors of not RTW among patients with BC.

A cross-sectional study and convenience sampling were conducted in two hospitals in Indonesia to recruit eligible participants. Factors related to not RTW were collected and included symptoms of distress, loneliness, anxiety/depression, perceived social support, and frailty. A logistic regression model was performed to explore associated factors of not RTW.

In total, 250 patients with BC were included in this study, and 148 of them experienced not RTW. Anxiety, loneliness, frailty, and social support emerged as significant factors associated with not RTW. BC patients who had a higher anxiety level (odds ratio [OR]: 5.30; 95% confidence interval [CI] [2.16, 12.98]), had high loneliness (OR: 3.15, 95% CI [1.29, 7.67]), or were frail (OR: 2.53; 95% CI [1.07, 5.98]) had a higher risk of not RTW. BC patients with lower social support (OR: 5.65; 95% CI [1.81, 17.63]) had a higher risk of not RTW.Conclusion/Applications to Practice:Occupational health professionals can offer early counseling, health education, and support strategies to patients with BC, assisting their preparations in terms of both physical and psychological functions for successfully RTW.

Multiple myeloma (MM) is an important hematological malignancy in older adults, with a relatively poor prognosis. We aimed to present the current global patterns of incidence and mortality from MM, and predict new cancer cases and deaths by 2045.

Estimated numbers of MM cases and deaths and age-standardized (World) incidence and mortality rates per 100 000 people were obtained from the GLOBOCAN 2022 database covering 185 countries. Based on the incidence and mortality rates for 2022 and UN population estimates up to 2045, cases and deaths were predicted up to 2045.

Globally, 188 000 MM cases and 121 000 deaths were estimated in 2022. Eastern Asia and Northern America accounted for one-fifth of all cases each (21% and 19% respectively), followed by South-Central Asia (11%), and Western Europe (9%). The incidence rates were higher in men than in women with similar geographical patterns. While the incidence rates were highest in Northern America and Australia/New Zealand (≥4/100 000 for both sexes combined), the highest mortality rates (1.8/100 000) were found in Australia/New Zealand, Northern Europe, and Southern Africa. In the absence of changing rates, the estimated incidence and mortality of MM will increase by 71% and 79%, respectively by 2045 relative to 2022.

Our study highlights the substantial burden and variations in MM incidence and mortality reflecting global disparities in diagnosis and treatment. Improved surveillance and better disease control is needed to mitigate the global impact of MM in the presence of population aging and growth.

Dose optimization in Phase I oncology trials balances therapeutic efficacy and patient safety. Traditional dose-escalation methods, such as the 3 + 3 design, primarily focus on safety, often resulting in prolonged exposure to subtherapeutic or excessively toxic doses. Additionally, these methods may fail to account for modern therapies' complex pharmacokinetics and pharmacodynamics, including targeted agents and immunotherapies. Contemporary approaches address these gaps by incorporating biomarkers, pharmacokinetic profiling, and patient-reported outcomes to guide personalized dosing strategies. Such methods improve the precision of dose selection and promote individualized cancer care. This review underscores the importance of distinguishing between dose-finding and dose optimization, advocating for designs that integrate patient perspectives and pharmacologic insights from early-phase trials. Additionally, we highlight the challenges of traditional methodologies and the importance of simplifying complex designs without compromising their scientific rigor. By embracing innovative approaches and patient-centered metrics, Phase I trials can evolve beyond safety assessments to expedite the delivery of effective and tailored cancer therapies.

Classic Hodgkin lymphoma (cHL) is defined by distinctive Hodgkin Reed-Sternberg (HRS) cells, which are CD30+/CD15+ multinucleated tumor cells lacking typical B-cell markers. These cells comprise <5 % of tumor mass but orchestrate an extensive immunosuppressive tumor microenvironment (TME). Classic HL was curable with radiation therapy and multi-agent chemotherapy. Despite high cure rates, treatment-related toxicities remain significant. The goals of multimodality therapy are to achieve a cure while minimizing treatment-associated toxicity. Advances in molecular insights into HRS cells have led to transformative therapies, including checkpoint inhibitors, antibody-drug conjugates like brentuximab vedotin, which have shown remarkable efficacy, especially in relapsed or refractory disease. However, challenges persist due to the heterogeneity of cHL, driven by the complex biology of HRS cells and their surrounding tumor microenvironment. Novel approaches such as single-cell RNA sequencing and circulating tumor DNA profiling provide promising strategies to address these challenges. This review examines the origin, morphology, phenotype, and genetic profiles of HRS cells, highlighting key pathobiological features, including biomarkers and Epstein-Barr Virus involvement. It also explores the biological mechanisms underlying HRS cell survival and evaluates standard and emerging therapies, offering insights into the rationale for novel treatment strategies.

Gastric cancer (GC) is the third leading cause of cancer-related deaths worldwide, with gastrectomy being the primary treatment option. Sepsis, a systemic inflammatory response to infection, may influence tumor growth by creating an immunosuppressive environment conducive to cancer cell proliferation and metastasis. Here, the effect of abdominal infection on tumor growth and metastasis was investigated through the implementation of a peritoneal metastasis model and a subcutaneous tumor model. In a murine model induced by cecal ligation and puncture (CLP) to simulate the effects of sepsis, we observed significant immune dysregulation, including T-cell exhaustion and the release of myeloid-derived suppressor cells (MDSCs). This immune alteration was associated with increased programmed cell death protein 1 (PD-1) expression on T cells and programmed cell death 1 ligand 1 (PD-L1) expression on MDSCs within the tumor microenvironment, fostering an immune-suppressive environment. Polymorphonuclear MDSCs (PMN-MDSCs) expressing elevated PD-L1 after sepsis demonstrated more substantial suppressive effects on T-cell proliferation than controls. Treatment with anti-PD-1 monoclonal antibodies successfully restored T-cell function, reduced mortality, and decreased metastasis in CLP mice. These findings emphasize the impact of sepsis on tumor progression and suggest targeting the PD-1/PD-L1 axis as a potential therapeutic strategy for managing immune dysfunction in patients with cancer.

Introduction: Prostate cancer is the most prevalent urogenital cancer among males. Radical prostatectomy remains the gold standard for localized prostate cancer treatment, with minimally invasive procedures (laparoscopic, robot-assisted laparoscopic) increasingly replacing open surgeries. YouTube™, a popular digital platform, hosts a substantial volume of prostate cancer-related videos, presenting a mix of accurate and misleading content. Given these challenges, researchers have proposed evaluation frameworks to assess the quality of YouTube™ videos. This study evaluates the educational adequacy and contextual relevance of laparoscopic radical prostatectomy (LRP) videos on YouTube™ using established video evaluation criteria. Methods: A search using the keyword "Laparoscopic Radical Prostatectomy" yielded 200 YouTube™ videos. After applying inclusion and exclusion criteria, 131 videos were analyzed by three laparoscopic prostatectomy specialists. An evaluation was performed using scoring systems, including LAP-VEGaS, DISCERN, JAMA, GQS, and video power index (VPI). Results: Of the 131 videos, 88 (67%) were from individual participants (Group 1), and 43 (33%) were from corporate channels (Group 2). Group 2 demonstrated significantly higher JAMA, GQS, and mDISCERN scores (P = .028, .005, and .001, respectively). The LAP-VEGaS score was also higher in Group 2 (7.09 ± 0.43) compared to Group 1 (5.08 ± 0.26; P < .001). VPI values were significantly greater in Group 2 (P = .008). Conclusion: This study highlights a critical gap in the educational quality of LRP videos on YouTube™. Using comprehensive scoring systems, corporate channels consistently provided higher-quality educational content compared to individual contributors.

Helicobacter pylori infection and the resulting inflammation of the stomach are widely recognized as the primary risk factors for the development of gastric cancer (human health). Despite numerous attempts, the correlation between various virulence factors of H. pylori and stomach cancer remains mainly unexplained. The cag pathogenicity island (cagPAI) is a widely recognized indicator of virulence in H. pylori. MicroRNAs play crucial roles in a wide range of biological and pathological processes and dysregulated expressions of miRNAs have been detected in numerous cancer types. However, research on the correlation between H. pylori infection and its cagPAI, as well as the differential expression of microRNAs in gastric cancer, is lacking.

The aim of this study was to examine the differential expression of miRNAs in 80 patients with gastric cancer, specifically in connection to the presence of H. pylori and its cag pathogenicity island (cagPAI).

Biopsies of 80 gastric cancer patients were collected and used for H. pylori DNA isolation and tissue miRNA isolation, and further analyzed for cagPAI and miRNA expression and their association.

Elevated levels of miR-21, miR-155, and miR-223 were detected in malignant tissues. The expression of miR-21 and miR-223 was considerably elevated in biopsies that tested positive for H. pylori, whereas the expression of miR-34a was reduced. H. pylori cagPAI samples that are functionally intact exhibit greater expression of miR-21 and miR-223 compared to cagPAI samples that are partially deleted, in both normal and malignant tissues.

Thus, the novelty of our study lies in its focus on the differential expression of specific miRNAs in relation to the functional integrity of the cagPAI in H. pylori-infected gastric cancer patients, offering a more detailed understanding of the interplay between H. pylori virulence factors and miRNA regulation than previous studies.

This study presents a personalized computational framework for modeling the vascular microenvironment in head-and-neck cancer patients and evaluating the impact of microvasculature on radiotherapy outcomes. We first perform a population-based calibration of a microvascular model using data collected with a sublingual microscope from 62 patients, creating synthetic networks that capture microvascular features with a population-based approach. The calibrated models accurately reproduce key physiological parameters, such as red blood cells velocity, aligning with clinical data. Next, we personalize the model for nine patients, demonstrating that digital patient-specific microvascular networks can replicate individual vascular beds' structural and functional characteristics. Simulations highlight that, while morphological features improve with vascularization, red blood cells velocity is less predictable, revealing the limitations of using capillary density alone to describe microvascular complexity. We then integrate these microvascular models into a 3D virtual microenvironment to simulate oxygen delivery and radiotherapy response. Our results show that higher vascularization enhances oxygenation and reduces hypoxic regions, which correlates with improved tumor control probability. Additionally, our findings demonstrate how the properties of microvascular networks, radiosensitivity, and treatment parameters affect predicted radiotherapy outcomes. Our workflow supports the creation of microvascular digital twins, initialized using patient data from sublingual microscopy.

The most important steps in thyroid surgery include distinguishing benign from malignant lesions and identifying the parathyroid glands. Optical coherence tomography (OCT) provides technical support for intraoperative guidance owing to its real-time, three-dimensional imaging capability. Benign and malignant diagnoses can be confirmed with intraoperative frozen sections; however, current approaches are time-consuming and labor-intensive and do not allow comprehensive, nondestructive tissue assessments. This study aimed to explore the use of OCT for imaging the thyroid tissue by verifying its clinical feasibility and qualitatively analyzing the OCT imaging characteristics of pathological thyroid glands. A customized swept-source OCT (SS-OCT) system was used to collect OCT data corresponding to the pathologies of 61 freshly excised tissue blocks containing either benign or malignant lesions from 45 patients. The OCT images were highly consistent with the H&E histological images, verifying the feasibility of OCT in producing suitable images for analysis. The OCT-derived characteristics of the thyroid tissue were as follows: normal thyroid follicles presented with regularly arranged honeycomb structures; follicular nodular disease (FND) was characterized by heterogeneous nodules composed of follicles of different sizes, with multiple nodules also differing in size and consisting of varied reticular structures and a focally solid appearance; lymphocyte aggregation led to a gray‒black appearance in Hashimoto's thyroiditis tumors; and papillary thyroid carcinoma lesions were characterized by a heterogeneous texture and a low penetration depth. These results demonstrate the imaging capabilities of OCT for thyroid tissue with different pathological conditions and its broad prospects for clinical application.

Research on the effects of herbal-derived natural active substances on cancer treatment and their combination with conventional treatments has intensified. This study analyzed the cytotoxic, genotoxic, apoptotic, and anticancer effects of combined treatment with 5-Fluorouracil (5-FU) and thymoquinone (TQ) on colorectal cancer. Cytotoxicity was evaluated using the ATP assay, DNA damage was assessed through the comet assay, apoptosis was measured via acridine orange/ethidium bromide staining and annexin V-FITC dye, and the expression of proapoptotic and antiapoptotic proteins was determined by western blot analysis. Transfected LoVo cells were injected subcutaneously into nude mice, and following treatment, oxidative stress and inflammation markers were examined in blood samples, while growth factors and vascularization markers were analyzed in tissue samples. The combination therapy at low concentrations resulted in increased cytotoxicity, DNA damage, apoptosis, and intracellular reactive oxygen species (p < 0.001), while simultaneously decreasing mitochondrial membrane potential and glutathione levels (p < 0.001), in comparison to monotherapy with TQ or 5-FU. Additionally, tissue levels of TGF-β1 and VEGF-α were significantly reduced (p < 0.001). Results demonstrates that while TQ or 5-FU alone have notable anticancer effects, their combination offers greater efficacy in mitigating molecular changes in both In Vitro and In Vivo models. Future studies should focus on optimizing the formulation, understanding the molecular mechanisms, and evaluating the efficacy and safety of the TQ and 5-FU combination across different cancer types.

Conjugation and loading of piroxicam and its metal complexes; Palladium(II) (PdL2) and Silver(I) (AgL) synthesized and characterized by different techniques including infrared, UV-Vis spectroscopy, spectrofluorimetry, transmission electron microscope, x-ray powder diffraction and Zeta potential analyses were achieved. Orange quantum dots (OQDs) nanoparticle showed good stability, encapsulation and loading efficiency and controlled release of loaded piroxicam and its metal complexes. Generally, new OQQs conjugates showed enhanced antimicrobial and anticancer activity.In vitroantimicrobial activity screening demonstrated thatAg(I)-OQDs conjugate displayed potent antibacterial effect that was 1.8-fold againstE. colihigher than piroxicam (MIC = 31.85µM), wherePd(II)-OQDs conjugate depicted the highest activity with MIC of 33.05µM againstP. aeruginosa. In case of G + ve bacteria,Agconjugate had potent activity which was 2.3-fold onS. aureushigher than piroxicam (MIC = 43.12µM), whilePdconjugate exerted promising activity that was 3.5-fold againstE. faecalishigher than piroxicam (MIC = 74.57µM).Agconjugate showed the most promising antifungal activity with 2.5-folds more than piroxicam. Thein vitroantiproliferative activity depicted that all synthesized conjugates showed better Cytotoxic effect than piroxicam, specificallyPdconjugate which had IC50 values with by 2-fold lower than piroxicam on human liver cancer cell lineHepg2.WhilePdandAgconjugates showed 2.3 and 1.9-fold higher effect on human colon cancer cell lineHT-29compared to piroxicam.

This study aimed to identify differential genes between pathological complete response (pCR) and non-pCR following neoadjuvant chemotherapy in triple-negative breast cancer (TNBC). Additionally, the expression and clinical significance of the differential gene SCNN1A in TNBC were explored.

Differential genes related to prognosis following neoadjuvant chemotherapy in TNBC were identified using the GEO database. Core genes were selected through the Cytoscape visualization and support vector machine (SVM) feature selection. The prognostic significance of these genes was assessed via online databases. SCNN1A expression and its correlation with clinicopathological data and neoadjuvant chemotherapy response were analyzed in 283 TNBC patients from the First Affiliated Hospital of Bengbu Medical University using immunohistochemistry.

Eleven core genes, including SCNN1A, were identified from 912 differential genes. High SCNN1A expression was associated with poor prognosis in TNBC patients via online database analysis. Gene set difference analysis (GSVA) and Gene set enrichment analysis (GSEA) revealed that SCNN1A was involved in several metabolic pathways. The clinical data indicated that high SCNN1A expression was associated with advanced T (p = 0.037) and N stages (p = 0.011), but not with age, HER2 status, Ki-67 expression, or histological grade. High SCNN1A expression was significantly more frequent in non-pCR patients compared to pCR patients, and high SCNN1A expression was associated with significantly lower overall survival (OS) and disease-free survival (DFS).

SCNN1A overexpression is associated with poor prognosis and non-pCR status in TNBC patients undergoing neoadjuvant chemotherapy.

Background/Objectives: We sought to evaluate the association between the risk of papillary thyroid carcinoma (PTC) and single-nucleotide polymorphisms (SNPs) of breast cancer genes 1 (BRCA1) and 2 (BRCA2). Methods: We prospectively recruited 515 cases with PTC and 296 controls without cancer. The genotypes of five BRCA1 SNPs (rs8176318, rs1799966, rs799917, rs16940, rs1799949) and three BRCA2 SNPs (rs15869, rs1799943, rs1799955) were determined using the TaqMan assay. We evaluated the association of haplotypes with the risk of PTC due to linkage disequilibrium (LD). Results: The five BRCA1 SNPs were significantly associated with the risk of PTC. The AC genotype of rs8176318 (OR = 0.69, p = 0.02) and the CT and CC genotypes of rs1799966 (OR = 0.70, p = 0.02 and OR = 0.67, p = 0.01, respectively) were associated with a decreased risk of PTC. The AG genotype of rs16940 (OR = 0.67, p = 0.01) and the AG genotypes of rs799917 and rs1799949 (both OR = 0.70, p = 0.02) decreased the risk of PTC. Haplotype 1 [rs8176318(C)-rs1799966(T)-rs799917(G)-rs16940(A)-rs1799949(G)] ± (OR = 0.69, p = 0.02) and haplotype 2 [rs8176318(A)-rs1799966(C)-rs799917(A)-rs16940(G)-rs1799949(A)] ± (OR = 0.71, p = 0.03) of BRCA1 reduced the risk of PTC. Conclusions: Our findings suggest that the polymorphisms of BRCA1 may contribute to the susceptibility to PTC in the Korean population.

Aim: To assess patient satisfaction with the breast care nurse (BCN) model and its adequacy in meeting patients' needs for information and support. Background: The BCN is a core multidisciplinary member of the breast cancer team. The evaluation of care models is necessary to detect gaps and improve the quality of care. Material and Methods: This cross-sectional descriptive study took place in a breast pathology unit and included patients with early breast cancer seen between 1 July 2016 and 30 June 2017 after finishing their treatment. Between July and December 2018, sociodemographic and clinical variables were collected from the clinical history, and satisfaction was measured using a questionnaire sent to the patients. Results: Of the 139 patients included, 99.3% reported that the BCN provided information correctly, 96.2% reported that she provided adequate information on self-care at home (96.2%), and 97.8% reported that the words of the BCN helped them feel better. However, some patients were unsure whether the BCN would have been willing to discuss alternative therapies (41%). Conclusions: Patients were satisfied with the BCN, including her role in meeting information and support needs. However, some issues needed to be sufficiently addressed. Comprehensive, continuous assessment is required to understand patient needs. Training and specific studies on topics that are of interest to patients can help respond to these needs. Implications for Nursing Management: BCN functions are being developed in some countries. BCN results make it easier for healthcare managers to commit to this role and for nurses to develop all their competencies. BCN models must respond to international guidelines but are also determined by organizational resources. The evaluation of these models is essential and must be considered by users. Advanced practice nursing roles, including the BCN, are well established in some countries but developing in others. BCN results make it easier for healthcare managers to commit to this role and for nurses to develop all their skills. BCN models must respond to the elements determined by organizations that work to improve the quality of care for patients with breast cancer. However, they are also determined by organizational resources. The evaluation of these models is essential to correct deficiencies and improve the quality of care. An important part of the evaluation must take into account the user who receives the care, in terms of satisfaction and the form of patient-reported outcome measures (PROMs).